Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



It's Up! It's Down! It's Dendreon!

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

They weren't the kind of monster moves we've seen in the past from Dendreon (Nasdaq: DNDN  ) , but shares were still volatile yesterday as a different news sent the stock in opposite directions.

On the positive side, news out of AstraZeneca (NYSE: AZN  ) helped the biotech. Yesterday, AstraZeneca announced that zibotentan, its potential competitor to Dendreon's prostate cancer treatment Provenge, failed one of its phase 3 trials.

Zibotentan is still in two other phase 3 trials. One is testing the drug in patients before the tumor has metastasized -- spread outside its primary location -- which shouldn't affect Provenge sales much since it's only approved for metastatic prostate cancer. The second trial is testing zibotentan in combination with sanofi-aventis' (NYSE: SNY  ) Taxotere, Provenge's current competitor. That trial could still be problematic for Provenge if Taxotere plus zibotentan extends survival more than Taxotere alone.

The bad news came later in the day after the Centers for Medicare & Medicaid Services (CMS) posted the questions for its Nov. 17 meeting to determine a national payment system for Provenge. The agency is questioning both its off-label and its on-label use.

Dendreon has secured reimbursement from insurers -- Aetna (NYSE: AET  ) , Humana (NYSE: HUM  ) , and Kaiser, in particular -- but Medicare is the mother lode considering the age of men who typically get prostate cancer. It's not a big deal if the agency restricts prescriptions for patients for which the Food and Drug Administration hasn't approved --  so called off-label use. But Dendreon needs reimbursement to include all the patients described on the label.

The evidence clearly points in the direction in Provenge working; that's why the FDA approved it, and the label is based on the clinical trials run by Dendreon. Unfortunately, the questions aren't yes-or-no answers. Instead the panel of experts are expected to rate their confidence on a scale of one to five. That leaves open the possibility of ambiguity, investors' worst enemy.

At the end of the day, after the ups and downs, Dendreon closed down just 1.3%. That's probably about right. As with its deal with GlaxoSmithKline (NYSE: GSK  ) last week securing a supply of a compound needed to make Provenge, investors just need to take each issue -- good or bad -- in stride. Keep an eye on the prize, Dendreon has a long and windy road until Provenge is a blockbuster.

Interested in keeping track of all the Dendreon news? Click here to add it to My Watchlist, which will help you keep track of all our Foolish analysis on Dendreon.

The Fool owns shares of GlaxoSmithKline, which is a Motley Fool Global Gains pick. Try any of our Foolish newsletter services free for 30 days.

True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Read/Post Comments (2) | Recommend This Article (78)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 28, 2010, at 8:03 PM, thecannula wrote:

    Hey Fool- You're pretty smart- but not quite as smart as David Urdan, who made news 2 weeks ago by selling 10k shares of DNDN while serving as the company's VP.....but guess what?, that was pocket change- the down payment on an Aspen ski house perhaps- HE KEPT 700K shares!

    Wonder if HE knows something you don't know?

  • Report this Comment On October 01, 2010, at 11:01 AM, stockpatterns wrote:

    Dendreon's volatile moves make it a perfect candidate for chart patterns strategies:

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1315064, ~/Articles/ArticleHandler.aspx, 10/27/2016 7:08:47 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 9 hours ago Sponsored by:
DOW 18,199.33 30.06 0.17%
S&P 500 2,139.43 -3.73 -0.17%
NASD 5,250.27 -33.13 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 4:01 PM
AET $111.01 Down -0.63 -0.56%
Aetna CAPS Rating: ***
AZN $29.59 Down -0.20 -0.67%
AstraZeneca CAPS Rating: ****
DNDNQ $0.00 Down +0.00 +0.00%
Dendreon Corp CAPS Rating: *
GSK $40.34 Up +0.02 +0.05%
GlaxoSmithKline CAPS Rating: ***
HUM $174.65 Down -0.21 -0.12%
Humana CAPS Rating: ****
SNY $37.06 Down -0.33 -0.88%
Sanofi CAPS Rating: *****